奥拉帕利维持单药治疗无胚系BRCA1/BRCA2突变的铂敏感复发性卵巢癌患者:OPINION主要分析
OPINION试验是一项单臂、开放标签、国际性研究,纳入279例无胚系BRCA1/BRCA2突变且接受过至少2线铂类化疗的铂敏感复发性卵巢癌患者,在铂类化疗应答后给予奥拉帕利片(300 mg每日两次)维持治疗。主要终点研究者评估的中位无进展生存期为9.2个月(95%CI 7.6-10.9),sBRCAm、HRD阳性(含sBRCAm)、HRD阳性(不含sBRCAm)和HRD阴性亚组的中位PFS分别为16.4、11.1、9.7和7.3个月。结论认为奥拉帕利维持治疗在无gBRCAm患者中及所有亚组中较历史安慰剂对照显示临床获益,无新安全性信号。
要点
- 无gBRCAm的铂敏感复发性卵巢癌患者接受奥拉帕利维持治疗,总体中位PFS为9.2个月(95%CI 7.6-10.9)。
- sBRCAm亚组中位PFS为16.4个月,HRD阳性(不含sBRCAm)为9.7个月,HRD阴性为7.3个月。
- 最常见治疗中出现的不良事件为恶心(48.4%)和乏力/无力(44.1%)。
核心结论
- 奥拉帕利维持治疗在无gBRCAm患者中及所有亚组中较历史安慰剂对照显示临床获益,无新安全性信号。
研究设计与样本
- IIIb期OPINION试验(NCT03402841),单臂、开放标签、国际性研究。
- 纳入279例无有害或疑似有害胚系BRCA1/BRCA2突变、铂敏感复发性卵巢癌且既往接受过至少2线铂类化疗的患者。
- 对铂类化疗应答的患者接受奥拉帕利片300 mg每日两次维持治疗,直至疾病进展或不可接受的毒性。
- 主要终点为研究者评估的无进展生存期(改良RECIST 1.1版)。
- 关键次要终点为按同源重组缺陷(HRD)和体细胞BRCAm(sBRCAm)状态分层的PFS。
主要发现
- 数据截止2020年10月2日,共发生210例PFS事件(成熟度75.3%),总体人群中位PFS为9.2个月(95%CI 7.6-10.9)。
- 12个月和18个月无进展生存比例分别为38.5%和24.3%。
- 预设生物标志物亚组中,sBRCAm、HRD阳性(含sBRCAm)、HRD阳性(不含sBRCAm)和HRD阴性患者的中位PFS分别为16.4、11.1、9.7和7.3个月。
- 最常见治疗中出现的不良事件(TEAE)为恶心(48.4%)和乏力/无力(44.1%)。
- TEAE导致剂量中断、剂量减少和治疗终止的患者比例分别为47.0%、22.6%和7.5%。
关键数值与推荐
- 奥拉帕利维持单药治疗剂量为300 mg片剂每日两次,直至疾病进展或不可接受的毒性。
- 主要终点PFS采用改良RECIST 1.1版由研究者评估。
- PFS主要分析计划在最后一名患者首次给药后18个月进行。
临床怎么用
- 对于无gBRCAm的铂敏感复发性卵巢癌患者,在铂类化疗应答后给予奥拉帕利维持单药治疗(300 mg每日两次)显示临床获益。
- 治疗期间需关注恶心和乏力/无力等常见不良事件,部分患者需剂量中断、减量或终止治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (gBRCAm) who had platinum-sensitive relapsed ovarian cancer (PSROC) and had received ≥2 previous lines of platinum-based chemotherapy. METHODS: In this single-arm, open-label, international study, patients who had responded to platinum-based chemotherapy received maintenance olaparib tablets (300 mg twice daily) until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed progression-free survival (PFS) (modified RECIST version 1.1). A key secondary endpoint was PFS by homologous recombination deficiency (HRD) and somatic BRCAm (sBRCAm) status. The primary analysis of PFS was planned for 18 months after the last patient received their first dose. RESULTS: Two hundred and seventy-nine patients were enrolled and received olaparib. At data cutoff (October 2, 2020), 210 PFS events had occurred (75.3% maturity) and median PFS was 9.2 months (95% confidence interval [CI], 7.6-10.9) in the overall population. At 12 and 18 months, 38.5% and 24.3% of patients were progression-free, respectively. In the predefined biomarker subgroups, median PFS was 16.4, 11.1, 9.7, and 7.3 months in sBRCAm, HRD-positive including sBRCAm, HRD-positive excluding sBRCAm, and HRD-negative patients, respectively. The most common treatment-emergent adverse events (TEAEs) were nausea (48.4%) and fatigue/asthenia (44.1%). TEAEs led to dose interruption, dose reduction, and treatment discontinuation in 47.0%, 22.6%, and 7.5% of patients, respectively. CONCLUSION: Maintenance olaparib demonstrated clinical benefit in patients without a gBRCAm, and across all subgroups, compared with historical placebo controls. There were no new safety signals.
引用
- Poveda A, Lheureux S, Colombo N, et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecol Oncol. 2022. PMID: 35063276. doi:10.1016/j.ygyno.2021.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。